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Morphea Affecting Bilateral Ankles
Katherine Kloberdanz DPM, PGY-1 and Chris Olenech DPM
Henry Ford Health System, Detroit, Michigan
Introduction

Images

Over the course of two years, our patient’s morphea, which
presented in a generalized pattern, flared into a more bullous
form. Her CellCept has been increased over time from 500 mg
TID to 1500 mg bid. Then in January 2020, the patient then
began complaining that the skin hardening was spreading and
that she had more difficulty walking. She was admitted to the
hospital to start a high-dose steroid regimen of SoluMedrol and
was later discharged on prednisone and with instructions to
continue her previous therapies. The patient reported some
resolution of symptoms after her most recent hospital encounter.
She continues to follow up with her rheumatologist,
dermatologist, and podiatrist.

Morphea, also known as localized scleroderma, is an
inflammatory disorder causing patches of hardened or discolored
skin and subcutaneous tissue and has an incidence of about 0.42.7 per 100,000. The five main types of morphea include linear,
plaque, generalized, deep, and bullous. More severe forms can
lead to devastating functional and cosmetic impairment due to
excessive collagen deposition in the deeper subcutaneous tissue.
Though thought to have an autoimmune component, there are no
clear immunological markers associated with morphea. Our case
highlights the difficult treatment course and possible correlation
between morphea and autoimmune diseases.

Clinical Presentation

Figure 1: Dorsal aspect of left foot

Figure 2: Lateral aspect of left foot

65-year old female presented to the podiatry clinic on 12/21/2018
complaining of increased swelling, pain, and skin darkening to
bilateral dorsal ankles and stiffening of her ankle joints for two
months. Patient stated her ankles felt ”raw and painful”. The
patient also noted that she had similar hyperpigmented plaques
on her back, neck, and upper extremities.
Past Medical History: Type 2 diabetes mellitus, hypertension,
hypothyroidism, arthritis, and Sjogren’s syndrome.
Past Surgical History: Bunion and hammertoe corrective surgery
left foot in 2014
Medications: Metformin, Hydrochlorothiazide, Levothyroxine,
and Restasis.
Family History: Sister with Raynaud’s syndrome

Conclusion
This case demonstrates the importance of a multi-disciplinary
approach to this lower extremity pathology. Though the exact
cause of morphea is unknown, the literature suggests there is an
increased incidence in patients with concurrent autoimmune
disease; Sjogren’s syndrome in this case. Therefore, having the
expertise from multiple disciplines available to diagnose and
treat these possibly related disease was greatly beneficial. By
having various specialties involved, a wide range of treatment
modalities were available to help alleviate her symptoms.
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Figure 3: Medial aspect of right foot

Figure 4: Medial aspect of left foot

Diagnosis
Physical exam revealed the patient was neurovascularly intact.
No local or generalized signs of vasculitis were noted. Patient did
have pain on palpation of the anterior aspects of bilateral ankles.
Localized edema 2+ was present to bilateral ankles.
Lab work performed previously by her rheumatologist revealed
she was ANA+, SSA+, SCL70-. The lesion on her neck had been
biopsied and showed dermal sclerosis consistent with morphea. It
was then determined clinically that the skin lesions affecting her
ankles were consistent with those on her neck and she was given
the diagnosis of generalized morphea.

Results

Treatment
Patient was initially started on the immunosuppressive drug
CellCept (mycophenolate mofetil) 500mg TID in 2018 by her
rheumatologist. She was then seen by a dermatologist in 2019
who added topical clobetasol, UVA1 phototherapy once a week,
and physical therapy to her regimen.
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